Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 16,142 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Dermatitis, Atopic
Interventions: Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 368 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Actinic Keratoses
Interventions: Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C); Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Cleveland, Ohio

Conditions: Erythematotelangiectatic Rosacea
Interventions: The Vbeam® Prima System, Oxymetazoline HCL 1% Cream; Device · Drug
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Charlotte, North Carolina • Houston, Texas

Conditions: Sanfilippo Syndrome Type C, Mucopolysaccharidosis (MPS) IIIC
Interventions: Not listed
Lead sponsor: Phoenix Nest; Industry
Eligibility: 1 Year to 25 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 91,758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2100
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Melanoma, Skin Neoplasms
Interventions: Imatinib mesylate (STI571); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: capecitabine; Drug
Lead sponsor: Pharmatech Oncology; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 10
States / cities: Lancaster, California • Orange, California • West Covina, California + 7 more

Conditions: Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
Interventions: Spedox-6, Pegfilgrastim, Filgrastim; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Orange, California

Conditions: Breast Cancer
Interventions: Computer Program, Focus Group, Written Materials, Questionnaires; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: El Paso, Texas • Houston, Texas

Conditions: Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
Interventions: M28z1XXPD1DNR CAR; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Bladder Cancer, Melanoma
Interventions: Nivolumab, Nivolumab plus Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Farmington, Connecticut • Middletown, New Jersey • Harrison, New York + 2 more

Conditions: Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Interventions: Tart Cherry, Omega 3 FA (Fish Oil); Drug
Lead sponsor: Philip Chang; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Torrance, California

Conditions: Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 2
States / cities: New York, New York

Conditions: Hyperhidrosis
Interventions: Ulthera System Treatment, Sham treatment; Drug
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Health Education, Questionnaire Administration; Behavioral · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Columbus, Ohio • Lima, Ohio • Richmond, Ohio + 1 more

Conditions: Androgenetic Alopecia
Interventions: 5 billion exosomes and saline solution microneedling, 50 billion exosomes and saline solution microneedling; Combination Product
Lead sponsor: Levit Dermatology; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Breast Cancer
Interventions: AeroForm Tissue Expansion, Saline Tissue Expansion; Device · Procedure
Lead sponsor: AirXpanders, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 17
States / cities: Greenbrae, California • Los Angeles, California • Orange, California + 12 more

Conditions: Genito-Urinary Neoplasm
Interventions: Biospecimen Collection(Punch Biopsy); Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Duarte, California

Conditions: Distal and Lateral Subungual Onychomycosis
Interventions: Luliconazole Solution, 10%, Vehicle Solution; Drug
Lead sponsor: Topica Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more

Conditions: Renal Cancer, Melanoma
Interventions: Aldesleukin, Sorafenib; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Arthritis, Psoriatic
Interventions: placebo, ustekinumab 45 mg, ustekinumab 90 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more

Conditions: Metastatic Breast Cancer
Interventions: Amrubicin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 28
States / cities: New Milford, Connecticut • Sharon, Connecticut • Torrington, Connecticut + 22 more

Conditions: HER2-negative Breast Cancer Patients With Brain Metastases
Interventions: Utidelone, Utidelone in combination with capecitabine; Drug
Lead sponsor: Biostar Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 9 more

Conditions: Systemic Lupus Erythematosus
Interventions: SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 22
States / cities: Vestavia Hills, Alabama • Chandler, Arizona • Mesa, Arizona + 19 more

Search by objective public record fields.

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

Natural History to Assess Disease in Patients With MPS IIIC

CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Cancer Genetics CD-ROM for Hispanics

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

Pancreas Registry and High Risk Registry

Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis

A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer

Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia

Patient Controlled Tissue Expansion for Breast Reconstruction

Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced Dermatitis

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus